The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…

Johnson & Johnson

Sanofi weighs Actelion offer to compete with J&J's $27B: Bloomberg

Astellas scouts pipeline buys for post-Xtandi future

What puts a new drug launch in line for victory? Ask Gilead, Biogen and J&J